Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Operations: 2009-2024

Historic Cash from Operations for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to -$455.6 million.

  • Madrigal Pharmaceuticals' Cash from Operations rose 219.21% to $79.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$160.6 million, marking a year-over-year increase of 62.74%. This contributed to the annual value of -$455.6 million for FY2024, which is 40.51% down from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Cash from Operations stood at -$455.6 million, which was down 40.51% from -$324.2 million recorded in FY2023.
  • Madrigal Pharmaceuticals' Cash from Operations' 5-year high stood at -$157.6 million during FY2020, with a 5-year trough of -$455.6 million in FY2024.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Cash from Operations value was -$324.2 million (recorded in 2023), while the average stood at -$334.9 million.
  • Data for Madrigal Pharmaceuticals' Cash from Operations shows a maximum YoY crashed of 278.53% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Cash from Operations stood at -$157.6 million in 2020, then dropped by 16.73% to -$183.9 million in 2021, then fell by 22.26% to -$224.9 million in 2022, then plummeted by 44.19% to -$324.2 million in 2023, then tumbled by 40.51% to -$455.6 million in 2024.